Published in Antimicrob Agents Chemother on February 01, 1987
Fluoroquinolone antimicrobial agents. Clin Microbiol Rev (1989) 6.45
In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother (1988) 4.03
In vitro activity of S-ofloxacin. Antimicrob Agents Chemother (1989) 2.10
Inhibition by quinolones of DNA gyrase from Staphylococcus aureus. Antimicrob Agents Chemother (1991) 1.93
Antimicrobial activity of DV-7751a, a new fluoroquinolone. Antimicrob Agents Chemother (1993) 1.86
In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother (1995) 1.80
Antagonism of wild-type and resistant Escherichia coli and its DNA gyrase by the tricyclic 4-quinolone analogs ofloxacin and S-25930 stereoisomers. Antimicrob Agents Chemother (1987) 1.74
Association between early inhibition of DNA synthesis and the MICs and MBCs of carboxyquinolone antimicrobial agents for wild-type and mutant [gyrA nfxB(ompF) acrA] Escherichia coli K-12. Antimicrob Agents Chemother (1988) 1.70
Uptake and intracellular activity of an optically active ofloxacin isomer in human neutrophils and tissue culture cells. Antimicrob Agents Chemother (1990) 1.51
Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrob Agents Chemother (1994) 1.51
Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis. Antimicrob Agents Chemother (1991) 1.17
Mechanism of differential activities of ofloxacin enantiomers. Antimicrob Agents Chemother (1996) 1.07
In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone. Antimicrob Agents Chemother (1991) 1.04
In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother (1996) 0.97
Novel 1-8-bridged chiral quinolones with activity against topoisomerase II: stereospecificity of the eukaryotic enzyme. Antimicrob Agents Chemother (1993) 0.91
Effect of DNA gyrase inhibitors pefloxacin, five other quinolones, novobiocin, and clorobiocin on Escherichia coli topoisomerase I. Antimicrob Agents Chemother (1987) 0.89
Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine. Antimicrob Agents Chemother (1996) 0.88
Susceptibility to levofloxacin predicted from in vitro susceptibility testing results obtained with ciprofloxacin and with ofloxacin. J Clin Microbiol (1995) 0.83
Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group. Antimicrob Agents Chemother (1996) 0.81
In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob Agents Chemother (1982) 21.31
Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci U S A (1977) 18.37
DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci U S A (1976) 17.42
Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci U S A (1977) 14.75
Replication of colicin E1 plasmid DNA in cell extracts. Proc Natl Acad Sci U S A (1974) 7.41
Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli. Antimicrob Agents Chemother (1986) 6.20
DNA gyrase: purification and catalytic properties of a fragment of gyrase B protein. Proc Natl Acad Sci U S A (1979) 4.34
DNA gyrase: affinity chromatography on novobiocin-Sepharose and catalytic properties. Nucleic Acids Res (1981) 4.16
Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA. Proc Natl Acad Sci U S A (1985) 3.18
Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob Agents Chemother (1986) 2.74
Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids. Antimicrob Agents Chemother (1986) 2.08
In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob Agents Chemother (1982) 21.31
Inhibition of development of Kaposi's sarcoma-related lesions by a bacterial cell wall complex. Science (1992) 6.35
High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes (2000) 4.55
Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother (1992) 4.43
In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother (1988) 4.03
Characterization of 21 newly established esophageal cancer cell lines. Cancer (1992) 2.87
Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology (1995) 2.85
Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob Agents Chemother (1986) 2.74
Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res (2000) 2.61
Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer (1998) 2.48
Association of genetic variation in FTO with risk of obesity and type 2 diabetes with data from 96,551 East and South Asians. Diabetologia (2011) 2.37
Primary structure of chicken skeletal muscle and fibroblast alpha-actinins deduced from cDNA sequences. Eur J Biochem (1988) 2.08
Synthesis and antibacterial activities of substituted 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxyl ic acids. Chem Pharm Bull (Tokyo) (1984) 1.99
Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Cell Death Differ (2005) 1.98
Inhibition by quinolones of DNA gyrase from Staphylococcus aureus. Antimicrob Agents Chemother (1991) 1.93
Human macrophage scavenger receptors: primary structure, expression, and localization in atherosclerotic lesions. Proc Natl Acad Sci U S A (1990) 1.87
Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology (1996) 1.86
Antimicrobial activity of DV-7751a, a new fluoroquinolone. Antimicrob Agents Chemother (1993) 1.86
Antimycoplasmal activity of ofloxacin (DL-8280). Antimicrob Agents Chemother (1983) 1.86
Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 1.84
Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer (1998) 1.82
Complete primary structure of vertebrate smooth muscle myosin heavy chain deduced from its complementary DNA sequence. Implications on topography and function of myosin. J Mol Biol (1987) 1.81
Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res (2001) 1.78
Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res (2000) 1.78
Nonrandom chromosomal imbalances in esophageal squamous cell carcinoma cell lines: possible involvement of the ATF3 and CENPF genes in the 1q32 amplicon. Jpn J Cancer Res (2000) 1.72
A systematic review of the clinical effectiveness and cost-effectiveness and economic modelling of minimal incision total hip replacement approaches in the management of arthritic disease of the hip. Health Technol Assess (2008) 1.70
Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob Agents Chemother (1997) 1.70
Percutaneous microwave coagulation therapy for solitary metastatic liver tumors from colorectal cancer: a pilot clinical study. Am J Gastroenterol (1999) 1.69
An ultrastructural study of subacute necrotizing lymphadenitis. Am J Pathol (1982) 1.66
Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology (1996) 1.65
Differential distribution of subsets of myofibrillar proteins in cardiac nonstriated and striated myofibrils. J Cell Biol (1990) 1.65
Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer (1998) 1.61
Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma: comparison with percutaneous ethanol injection therapy. Cancer (1999) 1.56
alpha-Actinin and vinculin are PIP2-binding proteins involved in signaling by tyrosine kinase. J Biol Chem (1994) 1.54
Caveolin-3 deficiency causes muscle degeneration in mice. Hum Mol Genet (2000) 1.53
Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol (2008) 1.52
Hepatic infarction following percutaneous ethanol injection therapy for hepatocellular carcinoma. Eur J Gastroenterol Hepatol (1998) 1.51
Progression of esophageal carcinoma by loss of EGF-STAT1 pathway. Cancer J (2001) 1.49
Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer (2000) 1.43
Infant schistosomiasis in Ghana: a survey in an irrigation community. Trop Med Int Health (2004) 1.41
Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol (2001) 1.41
Survival of patients with cancer of the pancreas in relation to findings on arteriography. Ann Surg (1972) 1.40
Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus. Antimicrob Agents Chemother (1989) 1.39
Growth suppression of esophageal cancer cells by p16INK4 and p15INK4B in vitro. Cancer J Sci Am (2006) 1.39
Shape memory in hydrogels. Nature (1995) 1.38
Urokinase-type plasminogen activator and its receptor in bladder cancer. J Natl Cancer Inst (1997) 1.37
Effects of Helicobacter pylori infection on Zollinger-Ellison syndrome. J Gastroenterol (2000) 1.37
Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers. Oncology (1999) 1.37
Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites. Antimicrob Agents Chemother (1989) 1.34
Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method. Cancer Lett (1998) 1.32
Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest (1994) 1.32
Lymph node ultrastructure in Hand-Schüller-Christian disease. Cancer (1971) 1.32
Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger-Ellison syndrome. Ann Surg (1987) 1.32
Loss of the sarcoglycan complex and sarcospan leads to muscular dystrophy in beta-sarcoglycan-deficient mice. Hum Mol Genet (1999) 1.32
Early and late complications of pylorus-preserving pancreatoduodenectomy in Japan 1998. J Hepatobiliary Pancreat Surg (1999) 1.31
Rapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percutaneous radiofrequency ablation in the primary tumour region. Eur J Gastroenterol Hepatol (2001) 1.30
Methylation of the 5' CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res (1998) 1.28
Altered expression of E-cadherin in gastric cancer tissues and carcinomatous fluid. Br J Cancer (1992) 1.27
Development and assessment of morphologic criteria for diagnosing gastric cancer using confocal endomicroscopy: an ex vivo and in vivo study. Endoscopy (2006) 1.24
Biochemical evidence for association of dystrobrevin with the sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy. Hum Mol Genet (2000) 1.23
SNO is a probable target for gene amplification at 3q26 in squamous-cell carcinomas of the esophagus. Biochem Biophys Res Commun (2001) 1.23
Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology (2000) 1.23
The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol (2008) 1.22
Effect of L18-MDP(Ala), a synthetic derivative of muramyl dipeptide, on nonspecific resistance of mice to microbial infections. Infect Immun (1982) 1.22
Expression level, subcellular distribution and rho-GDI binding affinity of merlin in comparison with Ezrin/Radixin/Moesin proteins. Oncogene (1999) 1.22
Mechanisms of 4-quinolone resistance in quinolone-resistant and methicillin-resistant Staphylococcus aureus isolates from Japan and China. J Med Microbiol (1995) 1.21
Massage for low back pain. Cochrane Database Syst Rev (2002) 1.21
Major histocompatibility complex class I-restricted infiltration and destruction of pancreatic islets by NOD mouse-derived beta-cell cytotoxic CD8+ T-cell clones in vivo. Diabetes (1996) 1.20
Seventeen year follow-up of a patient with hypertrophic cardiomyopathy which progressed to dilated cardiomyopathy. Jpn Heart J (1984) 1.20
Outbreak of nosocomial urinary tract infections caused by Serratia marcescens. J Clin Microbiol (1984) 1.20
Possible paracrine mechanism of insulin-like growth factor-2 in the development of liver metastases from colorectal carcinoma. Cancer (1999) 1.19
Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer (2000) 1.19
Immunofluorescent study on the pathogenesis of oral infection of poliovirus in monkeys. Jpn J Med Sci Biol (1967) 1.16
Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care (2000) 1.16
Physiological role of sinusoidal endothelial cells and Kupffer cells and their implication in the pathogenesis of liver injury. J Hepatobiliary Pancreat Surg (2000) 1.16
Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev (2000) 1.16
Role of Bcl-2 family proteins (Bax, Bcl-2 and Bcl-X) on cellular susceptibility to radiation in pancreatic cancer cells. Eur J Cancer (1999) 1.15
Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res (1993) 1.15
Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer (1998) 1.14
Physical and functional interaction of rabphilin-3A with alpha-actinin. J Biol Chem (1996) 1.14
Comparison of DNA fingerprinting by PFGE and PCR-RFLP of the coagulase gene to distinguish MRSA isolates. J Hosp Infect (1996) 1.13
A patient with improvement of ulcerative colitis after appendectomy. Gastroenterology (2000) 1.13
Expression of METH-1 and METH-2 in pancreatic cancer. Clin Cancer Res (2001) 1.13
Desmuslin, an intermediate filament protein that interacts with alpha -dystrobrevin and desmin. Proc Natl Acad Sci U S A (2001) 1.13
Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer (2000) 1.13
External and intraoperative radiotherapy for resectable and unresectable pancreatic cancer: analysis of survival rates and complications. Int J Radiat Oncol Biol Phys (1997) 1.13
Active efflux of ofloxacin by a highly quinolone-resistant strain of Proteus vulgaris. J Antimicrob Chemother (1991) 1.12
Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med (1997) 1.12
Monoclonal origin of an esophageal carcinosarcoma producing granulocyte-colony stimulating factor: a case report. Cancer (1998) 1.12
Effect of calcium on the cell infectivity of virulent Shigella flexneri 2a. Jpn J Microbiol (1974) 1.11
Persistent oxidative stress in human colorectal carcinoma, but not in adenoma. Free Radic Biol Med (1999) 1.11
Preparation of monoclonal antibody to V antigen from Yersinia pestis. Contrib Microbiol Immunol (1991) 1.11
Massive apoptosis in infantile myofibromatosis. A putative mechanism of tumor regression. Am J Pathol (1994) 1.11
Percutaneous double catheter infusion technique for the treatment of carcinoma in the abdomen. Surg Gynecol Obstet (1972) 1.10